Mohammad Amen Wattad

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial

Daniela Weber, Julia Krzykalla, Walter Fiedler, Michael W.M. Kühn et autres

de, at (code pays fourni par la source)

Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

Hartmut Döhner, Daniela Weber, Julia Krzykalla, Walter Fiedler et autres

de, at (code pays fourni par la source)

Evaluation of Exposure Index Values for Conventional Radiology Examinations: Retrospective Study in Governmental Hospitals at West Bank, Palestine

Muntaser S. Ahmad, Mohammad Shareef, Mohammad Amen Wattad, Nora Alabdullah et autres

In the digital radiology system, radiologic technologists (RTs) can choose imaging parameters to include kVp and mAs. The RTs received feedback after acquisition of an image in the form of Exposure Index (EI). The aim of the current study was to check …

ps (code pays fourni par la source)

Correction: High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Rüdiger Hehlmann, Astghik A. Voskanyan, Michael Lauseker, Markus Pfirrmann et autres

de, ch, it (code pays fourni par la source)

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

Rüdiger Hehlmann, Astghik A. Voskanyan, Michael Lauseker, Markus Pfirrmann et autres

Blast crisis is one of the remaining challenges in chronic myeloid leukemia (CML). Whether additional chromosomal abnormalities (ACAs) enable an earlier recognition of imminent blastic proliferation and a timelier change of treatment is unknown. One thousand five hundred and ten imatinib-treated patients …

de, ch, it (code pays fourni par la source)

Measurable Residual Disease (MRD) Monitoring in Acute Myeloid Leukemia (AML) with t(8;21)(q22;q22.1) RUNX1-RUNX1T1 Identifies Patients at High Risk of Relapse: Results of the AML Study Group (AMLSG)

Frank G. Rücker, Mridul Agrawal, Andrea Corbacioglu, Daniela Weber et autres

Background: Acute myeloid leukemia (AML) with t(8;21)(q22;q22.1) resulting in the RUNX1-RUNX1T1 gene fusion is considered favorable in the 2017 genetic risk stratification by the European LeukemiaNet (ELN). After intensive chemotherapy most patients (pts) achieve complete remission (CR), but relapse occurs in about …

de, at (code pays fourni par la source)

Evaluation of dose intensification of cytarabine in postremission therapy in older AML patients within the prospective phase II AMLSG 06-04 study

L. Häcker, Michela Giulia Tassara, Peter Brossart, Gerhard Held et autres

de, it, at (code pays fourni par la source)

The relationship between serum levels of prolactin and growth hormone in the early postnatal period

Jonathan Daliot, Tami Laron-Kenet, Mohammad Amen Wattad, Anat Ben-Dor et autres

il (code pays fourni par la source)

Minimal Residual Disease Monitoring in Acute Myeloid Leukemia (AML) with Translocation t(8;21)(q22;q22): Results of the AML Study Group (AMLSG)

Mridul Agrawal, Andrea Corbacioglu, Peter Paschka, Daniela Weber et autres

Abstract Background: Acute myeloid leukemia (AML) with t(8;21)(q22;q22) results in the formation of the RUNX1-RUNX1T1 fusion transcript which can be used to monitor minimal residual disease (MRD) by quantitative reverse transcriptase polymerase chain reaction (qRT-PCR). Early identification of patients (pts) with a …

de, at (code pays fourni par la source)

Real Life Experience with ATRA-Arsenic Trioxide Based Regimen in Acute Promyelocytic Leukemia - Updated Results of the Prospective German Intergroup Napoleon Registry

Uwe Platzbecker, Eva Lengfelder, Katharina S. Goetze, Christoph Röllig et autres

Abstract Background: Standard therapy of acute promyelocytic leukemia has long relied on the combination of All-trans-retinoic acid (ATRA) and chemotherapy. The introduction of arsenic trioxide (ATO) in APL treatment has allowed achievement of similarly high remission and survival rates coupled with significantly …

de, at (code pays fourni par la source)

Phase I/II Study on Cytarabine and Idarubicin Combined with Escalating Doses of Clofarabine in Untreated Patients with Acute Myeloid Leukemia and High Risk for Induction Failure (AMLSG 17-10 CIARA)

Juergen Krauter, Walter Fiedler, Richard F. Schlenk, Peter Paschka et autres

Abstract Background: Clofarabine is a second-generation purine nucleoside analogue, which has shown synergistic activity with cytarabine. We determined the maximum tolerated dose (MTD, primary endpoint), safety and efficacy (secondary endpoints) of clofarabine in combination with cytarabine and idarubicin in newly diagnosed acute …

de (code pays fourni par la source)

Condensed Versus Standard Schedule of High-Dose Cytarabine Consolidation Therapy with Pegfilgrastim Growth Factor Support in Acute Myeloid Leukemia

Sonia Jaramillo, Axel Benner, Jürgen Krauter, Hans W. Martin et autres

Abstract Background: The concept of intensive post-remission chemotherapy in acute myeloid leukemia (AML) is based on the observation that despite achievement of a first complete remission (CR) after intensive induction therapy virtually all patients relapse in the absence of further treatment. Moreover, …

de, at (code pays fourni par la source)